Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial

Author： Stadler Rudolf   Luger Thomas   Bieber Thomas   Köhler Ulrike   Linse Ruthild   Technau Kristin   Schubert Roland   Schroth Katja   Vakilzadeh Feredoun   Volkenandt Matthias   Gollnick Harald   Von Eick Harald   Thoren Fredrik   Strannegård Örjan  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.45, Iss.4, 2006-06, pp. : 389-399

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dacarbazine, Vincristine, Bleomycin and Lomustine plus Natural Interferon-alpha for Metastatic Melanoma

By Reinhold U.   Bruske T.   Kreysel H.W.  

European Journal of Cancer, Vol. 32, Iss. 1, 1996-01 ,pp. : 180-180

Elsevier

Access to resources Recommend Favorite

Fotemustine and Dacarbazine Plus Recombinant Interferon Alpha2a in the Treatment of Advanced Melanoma

By Comella P.   Daponte A.   Casaretti R.   Ionna F.   Fiore F.   Presutti F.   Frasci G.   Caponigro F.   Gravina A.   Parziale A.P.   Mozzillo N.   Comella G.  

European Journal of Cancer, Vol. 33, Iss. 8, 1997-07 ,pp. : 1326-1329

Elsevier

Access to resources Recommend Favorite

Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma: A single institution's experience

By Tas Faruk   Kurul Sidika   Camlica Hakan   Topuz Erkan  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 471-477

Humana Press, Inc

Access to resources Recommend Favorite

Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer-a multicentre, open, controlled, prospectively randomised trial

By von Minckwitz G.   Loibl S.   Brunnert K.   Kreienberg R.   Melchert F.   Mosch R.   Neises M.   Schermann J.   Seufert R.   Stiglmayer R.   Stosiek U.   Kaufmann   for the South West German Gynecologic Oncology Group SWGGOG  

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2265-2271

Elsevier

Access to resources Recommend Favorite

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

By Brandberg Yvonne   Johansson Hemming   Aamdal Steinar   Bastholt Lars   Hernberg Michaela   Stierner Ulrika   von der Maase Hans   Hansson Johan    

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1086-1093

Informa Healthcare

Access to resources Recommend Favorite